How  	How  	 WRB	O
immunotherapy  	immunotherapy  	 NNS	B-NP
can  	can  	 MD	O
enhance  	enhance  	 VB	O
the  	the  	 DT	O
response  	response  	 NN	O
to  	to  	 TO	O
other  	other  	 JJ	O
modalities  	modalities  	 NN	O
and  	and  	 CC	O
improve  	improve  	 VB	O
outcome  	outcome  	 NN	O
and  	and  	 CC	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
Early  	Early  	 RB	O
studies  	studies  	 VBZ	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
induction  	induction  	 NN	B-NP
of  	of  	 IN	O
an  	an  	 DT	O
effective  	effective  	 JJ	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
could  	could  	 MD	O
lead  	lead  	 VB	O
to  	to  	 TO	O
elimination  	elimination  	 NN	O
of  	of  	 IN	O
residual  	residual  	 JJ	B-NP
tumour 	tumour 	 NN	I-NP
.  	.  	 .	O
Over  	Over  	 IN	O
a  	a  	 DT	O
hundred  	hundred  	 CD	O
years  	years  	 NNS	O
ago  	ago  	 IN	O
Coley  	Coley  	 NNP	O
invented  	invented  	 VBD	O
his  	his  	 PRP$	O
eponymous  	eponymous  	 NNS	B-NP
named  	named  	 VBN	O
toxins  	toxins  	 NNS	O
that  	that  	 WDT	O
appeared  	appeared  	 VBD	O
to  	to  	 TO	O
induce  	induce  	 VB	O
a  	a  	 DT	O
strong  	strong  	 JJ	O
inflammatory  	inflammatory  	 JJ	B-NP
response 	response 	 NN	I-NP
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
tumour  	tumour  	 VB	O
reduction 	reduction 	 NN	O
.  	.  	 .	O
Subsequent  	Subsequent  	 JJ	B-NP
attempts  	attempts  	 NNS	I-NP
to  	to  	 TO	O
enhance  	enhance  	 VB	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
have  	have  	 VBP	O
essentially  	essentially  	 RB	O
been  	been  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
vaccine  	vaccine  	 NN	B-NP
basis 	basis 	 NN	I-NP
,  	,  	 ,	O
trying  	trying  	 VBG	O
to  	to  	 TO	O
induce  	induce  	 VB	O
a  	a  	 DT	O
specific  	specific  	 JJ	O
response  	response  	 NN	O
against  	against  	 IN	O
the  	the  	 DT	O
tumour 	tumour 	 NN	O
.  	.  	 .	O
Numerous  	Numerous  	 JJ	B-NP
vaccine  	vaccine  	 NN	I-NP
approaches  	approaches  	 NNS	I-NP
have  	have  	 VBP	O
claimed  	claimed  	 VBN	O
to  	to  	 TO	O
give  	give  	 VB	O
significant  	significant  	 JJ	O
clinical  	clinical  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
response  	response  	 NN	I-NP
but  	but  	 CC	O
very  	very  	 RB	O
few  	few  	 JJ	O
of  	of  	 IN	O
these  	these  	 DT	O
have  	have  	 VBP	O
survived  	survived  	 VBN	O
a  	a  	 DT	O
randomised  	randomised  	 JJ	B-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
major  	major  	 JJ	O
reason  	reason  	 NN	O
for  	for  	 IN	O
this  	this  	 DT	O
is  	is  	 VBZ	O
the  	the  	 DT	O
heterogeneity  	heterogeneity  	 NN	B-NP
of  	of  	 IN	O
many  	many  	 JJ	O
tumours 	tumours 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
various  	various  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
defence  	defence  	 NN	O
against  	against  	 IN	O
an  	an  	 DT	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
that  	that  	 IN	O
they  	they  	 PRP	O
employ 	employ 	 VBP	O
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
thought  	thought  	 VBN	O
that  	that  	 IN	O
chemotherapy  	chemotherapy  	 NN	O
and  	and  	 CC	O
radiotherapy  	radiotherapy  	 NNS	O
were  	were  	 VBD	O
mutually  	mutually  	 RB	O
exclusive  	exclusive  	 JJ	B-NP
for  	for  	 IN	I-NP
immunotherapy  	immunotherapy  	 NNS	I-NP
using  	using  	 VBG	O
the  	the  	 DT	O
vaccine  	vaccine  	 NN	B-NP
approach 	approach 	 NN	I-NP
.  	.  	 .	O
More  	More  	 RBR	O
recently 	recently 	 RB	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
become  	become  	 VBN	O
appreciated  	appreciated  	 VBN	O
that  	that  	 IN	O
vaccine  	vaccine  	 NN	B-NP
approaches  	approaches  	 NNS	I-NP
may  	may  	 MD	O
enhance  	enhance  	 VB	O
subsequent  	subsequent  	 JJ	O
responses  	responses  	 NNS	O
to  	to  	 TO	O
radiotherapy  	radiotherapy  	 VB	O
and  	and  	 CC	O
that  	that  	 DT	O
certain  	certain  	 JJ	O
chemotherapies  	chemotherapies  	 NNS	O
actually  	actually  	 RB	O
enhance  	enhance  	 VB	O
responses  	responses  	 NNS	O
to  	to  	 TO	O
vaccines 	vaccines 	 NNS	O
.  	.  	 .	O
It  	It  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
mechanisms  	mechanisms  	 NNS	O
of  	of  	 IN	O
action  	action  	 NN	O
of  	of  	 IN	O
chemotherapy  	chemotherapy  	 NN	O
is  	is  	 VBZ	O
to  	to  	 TO	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
cells  	cells  	 NNS	O
that  	that  	 IN	O
suppress  	suppress  	 JJ	O
T-cells 	T-cells 	 NN	B-NP
.  	.  	 .	O
These  	These  	 DT	O
cells  	cells  	 NNS	O
primarily  	primarily  	 RB	O
defend  	defend  	 VB	O
the  	the  	 DT	O
tumour  	tumour  	 NN	O
from  	from  	 IN	O
an  	an  	 DT	O
immunological  	immunological  	 JJ	B-NP
attack 	attack 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
more  	more  	 RBR	O
recently  	recently  	 RB	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
benefit  	benefit  	 NN	O
may  	may  	 MD	O
encompass  	encompass  	 VB	O
other  	other  	 JJ	O
aspects 	aspects 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
enhancing  	enhancing  	 VBG	O
antiangiogenic  	antiangiogenic  	 JJ	B-NP
responses 	responses 	 NNS	I-NP
.  	.  	 .	O
One  	One  	 CD	O
reason  	reason  	 NN	O
why  	why  	 WRB	O
immunostimulatory  	immunostimulatory  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
so  	so  	 RB	O
useful  	useful  	 JJ	O
in  	in  	 IN	O
cancer  	cancer  	 NN	O
is  	is  	 VBZ	O
that  	that  	 DT	O
many  	many  	 JJ	O
cancers  	cancers  	 NNS	O
evolve  	evolve  	 VB	O
out  	out  	 RP	O
of  	of  	 IN	O
a  	a  	 DT	O
chronic  	chronic  	 JJ	B-NP
inflammatory  	inflammatory  	 JJ	I-NP
environment  	environment  	 NN	I-NP
that  	that  	 WDT	O
actively  	actively  	 RB	O
suppresses  	suppresses  	 JJ	O
cell  	cell  	 NN	O
mediated  	mediated  	 VBZ	O
immune  	immune  	 JJ	O
responses  	responses  	 NNS	O
and  	and  	 CC	O
enhances  	enhances  	 VBZ	O
tumour  	tumour  	 JJ	B-NP
angiogenesis 	angiogenesis 	 NN	I-NP
.  	.  	 .	O
An  	An  	 DT	O
ideal  	ideal  	 JJ	O
cancer  	cancer  	 NN	B-NP
drug  	drug  	 NN	I-NP
would  	would  	 MD	O
therefore  	therefore  	 RB	O
be  	be  	 VB	O
expected  	expected  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
these  	these  	 DT	O
properties 	properties 	 NNS	O
.  	.  	 .	O
One  	One  	 CD	O
such  	such  	 JJ	O
drug  	drug  	 NN	O
is  	is  	 VBZ	O
lenalidomide 	lenalidomide 	 VBN	O
,  	,  	 ,	O
which  	which  	 WDT	O
features  	features  	 NNS	O
include  	include  	 VBP	O
marked  	marked  	 VBN	O
immune  	immune  	 JJ	O
stimulatory  	stimulatory  	 JJ	B-NP
properties  	properties  	 NNS	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
being  	being  	 VBG	O
able  	able  	 JJ	O
to  	to  	 TO	O
inhibit  	inhibit  	 VB	O
regulatory  	regulatory  	 JJ	B-NP
T-cells 	T-cells 	 NN	I-NP
.  	.  	 .	O
They  	They  	 PRP	O
have  	have  	 VBP	O
also  	also  	 RB	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
enhance  	enhance  	 VB	O
anticancer  	anticancer  	 JJ	B-NP
activity  	activity  	 NN	I-NP
with  	with  	 IN	O
vaccines  	vaccines  	 NNS	O
in  	in  	 IN	O
both  	both  	 DT	O
preclinical  	preclinical  	 JJ	B-NP
models  	models  	 NNS	I-NP
and  	and  	 CC	O
more  	more  	 RBR	O
recently  	recently  	 RB	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
observations 	observations 	 NNS	I-NP
,  	,  	 ,	O
where  	where  	 WRB	O
the  	the  	 DT	O
responses  	responses  	 NNS	O
to  	to  	 TO	O
vaccines  	vaccines  	 VB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
myeloma  	myeloma  	 NN	B-NP
is  	is  	 VBZ	O
much  	much  	 RB	O
higher  	higher  	 JJR	O
when  	when  	 WRB	O
they  	they  	 PRP	O
are  	are  	 VBP	O
on  	on  	 IN	O
lenalidomide  	lenalidomide  	 NN	B-NP
than  	than  	 IN	O
other  	other  	 JJ	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
A  	A  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
regularly  	regularly  	 RB	O
used  	used  	 VBN	O
chemotherapy  	chemotherapy  	 JJ	O
regimens  	regimens  	 NNS	O
have  	have  	 VBP	O
marked  	marked  	 VBN	O
activity  	activity  	 NN	O
in  	in  	 IN	O
modulating  	modulating  	 VBG	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
response 	response 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
maybe  	maybe  	 RB	O
of  	of  	 IN	O
benefit  	benefit  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
regimens  	regimens  	 NN	O
will  	will  	 MD	O
be  	be  	 VB	O
reviewed 	reviewed 	 VBN	O
,  	,  	 ,	O
which  	which  	 WDT	O
include  	include  	 VBP	O
gemcitabine 	gemcitabine 	 VBN	O
,  	,  	 ,	O
cyclophosphamide  	cyclophosphamide  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
IMiDs 	IMiDs 	 JJ	O
.  	.  	 .	O
